Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Outlook Therapeutics Inc OTLK

Healthcare Biotechnology
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD)... see more

Recent & Breaking News (NDAQ:OTLK)

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile December 15, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook Lawsuit - OTLK

Accesswire December 14, 2023

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK

Newsfile December 14, 2023

INVESTOR ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 - OTLK

Accesswire December 14, 2023

OTLK Class Action Alert: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 14, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - OTLK

Accesswire December 14, 2023

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile December 14, 2023

OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire December 14, 2023

INVESTOR ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

Accesswire December 14, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 - OTLK

Accesswire December 13, 2023

OTLK Class Action Alert: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 13, 2023

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your Rights - OTLK

Accesswire December 13, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile December 13, 2023

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire December 12, 2023

Outlook Ongoing Deadline Alert

Newsfile December 12, 2023

OTLK Class Action Alert: Bronstein, Gewirtz & Grossman LLC Reminds Outlook Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!

Accesswire December 12, 2023

INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your Rights - OTLK

Accesswire December 12, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK

Newsfile December 12, 2023

INVESTOR ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - OTLK

Accesswire December 12, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile December 12, 2023